Waters Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Udit Batra
- Full Time Employees
- 7,900
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 34 Maple Street Milford MA United States 01757
- IPO Date
- Nov 17, 1995
- CIK
- 0001000697
- Website
- waters.com
- Similar Companies
- Business
- Waters Corporation (NYSE: WAT), founded in 1958 and headquartered in Milford, Massachusetts, develops, manufactures, and markets analytical instruments, chromatography columns, and other consumables for the life sciences, pharmaceutical, biopharmaceutical, chemical, food, environmental, and clinical diagnostics industries worldwide. The company offers high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems such as the ACQUITY Premier and Alliance iS series; mass spectrometry instruments including the Xevo G3 QTof, Xevo TQ Absolute, SELECT SERIES MRT, and BioAccord LC-MS; gel permeation and size exclusion chromatography solutions; thermal analysis and rheology products through its TA Instruments division; light-scattering devices from Wyatt Technology; software platforms like Empower and waters_connect for data management and compliance; and related consumables, columns, detectors, and accessories used in drug discovery, development, manufacturing, food safety testing, environmental monitoring, and materials science applications across more than 100 countries with 12 manufacturing facilities and operations in 35 countries. Recent developments include the 2025 acquisition of Halo Labs to expand its biological analysis portfolio for advanced characterization in drug development; the July 2025 agreement to combine with BD's Biosciences and Diagnostic Solutions business in a $17.5 billion all-stock merger creating a leader in regulated life science and high-volume diagnostics testing; and the 2023 acquisition of Wyatt Technology enhancing its capabilities in macromolecular characterization and complex mixture analysis.
Company News
Jim Cramer Calls Big Tech ‘Millstones' and Names the ‘New Techs' Taking Over
Waters Q3 Earnings Call Highlights
Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised
Waters Corporation (WAT) Q3 2026 Earnings Call Transcript
Waters (WAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Waters (WAT) Beats Q3 Earnings and Revenue Estimates
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery
Waters Gears Up to Report Q3 Results: How to Play the Stock?
Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
First Eagle U.S. Value Fund Q3 2026 Portfolio Review
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows
Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
Two stocks poised to benefit from rotation out of AI
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Waters (NYSE:WAT) Reaches New 52-Week High – Time to Buy?
Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call